Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen

Por ter Heine, Rob, Binkhorst, Lisette, de Graan, Anne Joy M, de Bruijn, Peter, Beijnen, Jos H, Mathijssen, Ron H J, Huitema, Alwin D R
Publicado no Br J Clin Pharmacol (2014)

4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes

Por de Graan, Anne-Joy M, Sparreboom, Alex, de Bruijn, Peter, de Jonge, Evert, van der Holt, Bronno, Wiemer, Erik A C, Verweij, Jaap, Mathijssen, Ron H J, van Schaik, Ron H N
Publicado no Br J Clin Pharmacol (2015)

CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity

Por de Graan, Anne-Joy M., Elens, Laure, Sprowl, Jason A., Sparreboom, Alex, Friberg, Lena E., van der Holt, Bronno, de Raaf, Pleun J., de Bruijn, Peter, Engels, Frederike K., Eskens, Ferry A.L.M., Wiemer, Erik A.C., Verweij, Jaap, Mathijssen, Ron H.J., van Schaik, Ron H.N.
Publicado em 2013

Influence of Polymorphic OATP1B-Type Carriers on the Disposition of Docetaxel

Por de Graan, Anne-Joy M., Lancaster, Cynthia S., Obaidat, Amanda, Hagenbuch, Bruno, Elens, Laure, Friberg, Lena E., de Bruijn, Peter, Hu, Shuiying, Gibson, Alice A., Bruun, Gitte H., Corydon, Thomas J., Mikkelsen, Torben S., Walker, Aisha L., Du, Guoqing, Loos, Walter J., van Schaik, Ron H. N., Baker, Sharyn D., Mathijssen, Ron H. J., Sparreboom, Alex
Publicado em 2012